

ISPAD Clinical Practice Consensus Guidelines 2006–2007

Diabetic ketoacidosis

Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee WRW, Rosenbloom A, Sperling MA, Hanas R. Diabetic ketoacidosis.

Pediatric Diabetes 2007; 8: 28–42.

Joseph Wolfsdorf^a
Maria E Craig^b
Denis Daneman^c
David Dunger^d
Julie Edge^e
WR Warren Lee^f
Arlan Rosenbloom^g
Mark A Sperling^h and
Ragnar Hanasⁱ

^aDivision of Endocrinology, Children's Hospital Boston, MA, USA

^bSchool of Women's and Children's Health, University of New South Wales, Sydney, Australia

^cUniversity of Toronto, The Hospital for Sick Children, Toronto, Canada

^dDepartment of Paediatrics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

^eDepartment of Paediatrics, John Radcliffe Hospital, Oxford, UK

^fEndocrinology Service Department of Paediatric Medicine, KK Children's Hospital, Singapore

^gDivision of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL, USA

^hDepartment of Pediatric Endocrinology, Children's Hospital, University of Pittsburgh, PA, USA

ⁱDepartment of Pediatrics, Uddevalla Hospital, Uddevalla, Sweden

Corresponding author:

Ragnar Hanas, MD, PhD,
Department of Pediatrics, Uddevalla Hospital,
S-451 80 Uddevalla, Sweden.

Tel: +46-522-92000;

e-mail: ragnar.hanas@vgregion.se

Editors of the ISPAD Clinical Practice Consensus Guidelines 2006–2007; Ragnar Hanas, Kim Donaghue, Georgeanna Klingensmith, Peter Swift

Diabetic ketoacidosis (DKA) results from absolute or relative deficiency of circulating insulin and the combined effects of increased levels of the counter-regulatory hormones: catecholamines, glucagon, cortisol, and growth hormone (1, 2). Absolute insulin deficiency occurs in previously undiagnosed type 1 diabetes mellitus (T1DM) and when patients on treatment deliberately or inadvertently do not take insulin, especially the long-acting component of a basal-bolus regimen. Patients who use an insulin pump can rapidly develop DKA when insulin delivery fails for any reason. Relative insulin deficiency occurs when the concentrations of counter-regulatory hormones increase in response to stress in conditions such as sepsis, trauma, or gastrointestinal illness with diarrhea and vomiting. The pathophysiology of DKA in children is summarized in Fig. 1.

The combination of low serum insulin and high counter-regulatory hormone concentrations results in an accelerated catabolic state with increased glucose production by the liver and kidney (via glycogenolysis and gluconeogenesis), impaired peripheral glucose

utilization resulting in hyperglycemia and hyperosmolality, and increased lipolysis and ketogenesis, causing ketonemia and metabolic acidosis. Hyperglycemia that exceeds the renal threshold [approximately 10 mmol/L (180 mg/dL), although the range in normal and diabetic individuals is very wide] and hyperketonemia causes osmotic diuresis, dehydration, and obligatory loss of electrolytes, which often is aggravated by vomiting. These changes stimulate further stress hormone production, which induces more severe insulin resistance and worsening hyperglycemia and hyperketonemia. If this cycle is not interrupted with exogenous insulin and fluid and electrolyte therapy, fatal dehydration and metabolic acidosis will ensue. Ketoacidosis may be aggravated by lactic acidosis from poor tissue perfusion or sepsis.

DKA is characterized by severe depletion of water and electrolytes from both the intra- and extracellular fluid (ECF) compartments; the range of losses is shown in Table 1. Despite their dehydration, patients continue to maintain normal blood pressure and have considerable urine output until extreme volume depletion leads to a critical decrease in renal blood

Pathophysiology of Diabetic Ketoacidosis (DKA)




Fig. 1. Pathophysiology of diabetic ketoacidosis. Copyright © 2006 American Diabetes Association. From *Diabetes Care*, Vol. 29, 2006; 1150–1159. Reprinted with permission from *The American Diabetes Association*.

flow and glomerular filtration. At presentation, the magnitude of specific deficits in an individual patient varies depending upon the duration and severity of illness, the extent to which the patient was able to maintain intake of fluid and electrolytes, and the content of food and fluids consumed before coming to medical attention. Consumption of fluids with a high-carbohydrate content (juices or sugar containing soft drinks) exacerbates the hyperglycemia (3).

Clinical manifestations of DKA

- ◆ Dehydration
- ◆ Rapid, deep, sighing (Kussmaul respiration)
- ◆ Nausea, vomiting, and abdominal pain mimicking an acute abdomen
- ◆ Progressive obtundation and loss of consciousness

- ◆ Increased leukocyte count with left shift
- ◆ Non-specific elevation of serum amylase
- ◆ Fever only when infection is present

Definition of DKA

The **biochemical criteria** for the diagnosis of DKA are (4):

- ◆ Hyperglycemia (blood glucose > 11 mmol/L [\approx 200 mg/dL])
- ◆ Venous pH < 7.3 or bicarbonate < 15 mmol/L
- ◆ Ketonemia and ketonuria

Partially treated children and children who have consumed little or no carbohydrates may have, on rare occasion, only modestly increased blood glucose concentrations (“euglycemic ketoacidosis”) (5, 6).

Table 1. Losses of fluids and electrolytes in diabetic ketoacidosis (DKA) and maintenance requirements in normal children

	Average (range) losses per kg	24-h maintenance requirements
Water	70 mL (30–100)	* \leq 10 kg 100 mL/kg/24 h 11–20 kg 1000 mL + 50 mL/kg/24 h for each kg from 11–20 >20 kg 1500 mL + 20 mL/kg/24 h for each kg >20
Sodium	6 mmol (5–13)	2–4 mmol†
Potassium	5 mmol (3–6)	2–3 mmol
Chloride	4 mmol (3–9)	2–3 mmol
Phosphate	(0.5–2.5) mmol	1–2 mmol

Data are from measurements in only a few children and adolescents (41, 42, 80–82). In any individual patient, actual losses may be less or greater than the ranges shown in the Table (E).

Three methods for determining maintenance water requirements in children are commonly used: *the Holliday–Segar formula (143) (shown in this Table), a simplified Holliday–Segar formula† (see below), and a formula based on body surface area for children more than 10 kg (1500 mL/m²/24 h) (144).

†Maintenance electrolyte requirements in children are per 100 mL of maintenance IV fluid (144, 145).

‡Simplified method based on Holliday–Segar: <10 kg 4 mL/kg/h; 11–20 kg 40 + 2 mL/kg/h for each kg between 11 and 20; >20 kg 60 + 1 mL/kg/h for each kg >20.

Type 2 diabetes mellitus (T2DM), associated with increased rates and severity of obesity, in some centers now accounts for as much as one half of newly diagnosed diabetes in children aged 10–21 yr, depending on the socioeconomic and ethnic composition of the population (7). Acute decompensation with DKA has been recognized to occur at the time of diagnosis in as many as 25% of children with T2DM (7). This is more likely in those of African-American descent, less so in Hispanic, and least in Canadian First Nation teenagers (8–13). The majority of new cases of diabetes in Japanese children and adolescents are detected in asymptomatic individuals by routine urine screening (14, 15); however, overall, approximately 5% of patients with T2DM have DKA at the time of diagnosis (16).

The **severity of DKA** is categorized by the degree of acidosis (17):

- ◆ Mild: venous pH < 7.3 or bicarbonate < 15 mmol/L
- ◆ Moderate: pH < 7.2, bicarbonate < 10 mmol/L
- ◆ Severe: pH < 7.1, bicarbonate < 5 mmol/L

Hyperglycemic hyperosmolar state (HHS) also may occur in young patients with T2DM (18, 19). **The criteria for HHS** include (2):

- ◆ Plasma glucose concentration > 33.3 mmol/L (600 mg/dL)
- ◆ Arterial pH > 7.30
- ◆ Serum bicarbonate > 15 mmol/L
- ◆ Small ketonuria, absent to mild ketonemia (serum β -hydroxybutyrate 1 ± 0.2 (SEM) mmol/L (2))
- ◆ Effective serum osmolality > 320 mOsm/kg
- ◆ Stupor or coma

It is important to recognize that overlap between the characteristic features of HHS and DKA may occur. Some patients with HHS, especially when there is very severe dehydration, have mild or moderate acidosis. Conversely, some children with T1DM may have features of HHS (severe hyperglycemia) if high-carbohydrate-containing beverages have been used to quench thirst and replace urinary losses prior to diagnosis (3). Therapy must be appropriately modified to address the pathophysiology and unique biochemical disturbances of each individual patient.

Frequency of DKA

At disease onset

There is wide geographic variation in the frequency of DKA at onset of diabetes; rates inversely correlate with the regional incidence of T1DM. Frequencies range from approximately 15% to 70% in Europe and North America (A) (20–24). DKA at diagnosis is more common in younger children (<5 yr of age), and in children whose families do not have ready access to medical care for social or economic reasons (A) (6, 24, 25).

In children with established diabetes (recurrent DKA)

The risk of DKA in established T1DM is 1–10% per patient per year (A, C) (26–29).

Risk is increased in (28):

- ◆ Children with poor metabolic control or previous episodes of DKA
- ◆ Peripubertal and adolescent girls
- ◆ Children with psychiatric disorders, including those with eating disorders
- ◆ Children with difficult or unstable family circumstances (e.g., parental abuse)
- ◆ Children who omit insulin (30) (C)
- ◆ Children with limited access to medical services
- ◆ Insulin pump therapy (as only rapid-acting or short-acting insulin is used in pumps, interruption of insulin delivery for any reason rapidly leads to insulin deficiency) (29) (C)

Management of DKA

Emergency assessment

- ◆ Perform a clinical evaluation to **confirm the diagnosis** and determine its cause. Carefully look for evidence of infection. In recurrent DKA, insulin omission or failure to follow sick day or pump failure management guidelines accounts for almost all episodes, except for those because of acute severe febrile or gastrointestinal illness.
- ◆ **Weigh** the patient. (If body surface area is used for fluid therapy calculations, measure height or length to determine surface area.) This weight should be used for calculations and not the weight from a previous office visit or hospital record.
- ◆ **Assess clinical severity of dehydration.**
- ◆ Clinical assessment of dehydration is imprecise, inaccurate, and generally shows only fair to moderate agreement among examiners. It should be based on a combination of physical signs. The three most useful individual signs for assessing dehydration in young children and predicting at least 5% dehydration and acidosis are:
 - prolonged capillary refill time (normal capillary refill is ≤ 1.5 –2 s)
 - abnormal skin turgor ('tenting' or inelastic skin)
 - abnormal respiratory pattern (hyperpnea) (31)
- ◆ Other useful signs in assessing degree of dehydration include dry mucus membranes, sunken eyes, absent tears, weak pulses, and cool extremities. More signs of dehydration tend to be associated with more severe dehydration (31).

- $\geq 10\%$ dehydration is suggested by the presence of weak or impalpable peripheral pulses, hypotension, and oliguria.

- ◆ **Assess level of consciousness** [Glasgow coma scale (GCS) – see Table 2] (32).
- ◆ Obtain a **blood sample for laboratory measurement** of serum or plasma glucose, electrolytes (including bicarbonate or total carbon dioxide), blood urea nitrogen, creatinine, osmolality, venous (or arterial in critically ill patient) pH, pCO₂, hemoglobin and hematocrit or complete blood count (an increased white blood cell count in response to stress is characteristic of DKA and is not indicative of infection (22). The white cell count need not be measured unless there is evidence of concurrent infection), calcium, phosphorus, and magnesium concentrations (if possible), HbA1c.
- ◆ Perform a **urinalysis** for ketones.
- ◆ Measurement of blood β -hydroxybutyrate concentration, if available, is useful to confirm ketoacidosis and may be used to monitor the response to treatment (33, 34).
- ◆ Obtain appropriate **specimens for culture** (blood, urine, throat), if there is evidence of infection.
- ◆ If laboratory measurement of serum potassium is delayed, perform an **electrocardiogram** (ECG) for baseline evaluation of potassium status (35, 36).
- ◆ In the child with **established diabetes** (recurrent DKA) and suspected insulin omission, it may be useful to obtain a blood sample for determination of serum free insulin concentration (even when children have been treated exclusively with biosynthetic human insulin, anti-insulin antibodies may be present in the serum and interfere with insulin immunoassays. Thus anti-insulin antibodies must be eliminated before the concentration of free (active) insulin is determined (27)) before insulin is administered

because the history of recent insulin administration may not be available or accurate (37).

Supportive measures

- ◆ **Secure the airway** and empty the stomach by continuous nasogastric suction to prevent pulmonary aspiration in the unconscious or severely obtunded patient.
- ◆ A **peripheral intravenous (IV) catheter** should be placed for convenient and painless repetitive blood sampling. An **arterial catheter** may be necessary in some critically ill patients managed in an intensive care unit.
- ◆ A **cardiac monitor** should be used for continuous electrocardiographic monitoring to assess T waves for evidence of hyper- or hypokalemia (35, 36).
- ◆ Give **oxygen** to patients with severe circulatory impairment or shock.
- ◆ Give **antibiotics** to febrile patients after obtaining appropriate cultures of body fluids.
- ◆ **Catheterization of the bladder** is usually not necessary, but if the child is unconscious or unable to void on demand (e.g., infants and very ill young children) the bladder should be catheterized.

Where should the child be managed? The child should receive care in a unit that has:

- ◆ Experienced nursing staff trained in monitoring and management
- ◆ Written guidelines for DKA management in children
- ◆ Access to laboratories for frequent and timely evaluation of biochemical variables

A specialist/consultant pediatrician with training and expertise in the management of DKA should direct inpatient management.


Table 2. Glasgow coma scale or score. The GCS consists of three parameters and is scored between 3 and 15 (32); 3 being the worst and 15 the best. One of the components of the GCS is the best verbal response, which cannot be assessed in non-verbal young children. A modification of the GCS was created for children too young to talk.

Best eye response	Best verbal response	Best verbal response (non-verbal children)	Best motor response
1. No eye opening	1. No verbal response	1. No response	1. No motor response
2. Eyes open to pain	2. No words, only incomprehensible sounds; moaning and groaning	2. Inconsolable, irritable, restless, cries	2. Extension to pain (decerebrate posture)
3. Eyes open to verbal command	3. Words, but incoherent*	3. Inconsistently consolable and moans; makes vocal sounds	3. Flexion to pain (decorticate posture)
4. Eyes open spontaneously	4. Confused, disoriented conversation†	4. Consolable when crying and interacts inappropriately	4. Withdrawal from pain
	5. Orientated, normal conversation	5. Smiles, oriented to sound, follows objects and interacts	5. Localizes pain
			6. Obeys commands

*Inappropriate words, no sustained conversational exchange.

†Attention can be held; responds in a conversational manner, but shows some disorientation.

Immediate assessment



Adapted from Dunger et al. Karger Pub.1999. NG, nasogastric, SC,subcutaneous

Fig. 2. Algorithm for the immediate assessment and management of diabetic ketoacidosis (DKA).

Children with severe DKA (long duration of symptoms, compromised circulation, or depressed level of consciousness) or those who are at increased risk for cerebral edema (e.g., <5 yr of age, severe acidosis, low pCO₂, high blood urea nitrogen) should be considered for immediate treatment in an intensive care unit (pediatric, if available) or in a unit that has equivalent resources and supervision, such as a children's ward specializing in diabetes care (C,E) (4, 38).

In a child with **established diabetes**, whose parents have been trained in sick day management, hyperglycemia and ketosis without vomiting or severe dehydration can be managed at home or in an outpatient health care facility (e.g., emergency ward), provided an experienced diabetes team supervises the care (C,E) (17, 39, 40).

Children and adolescents with DKA should be managed in centers experienced in its treatment and where vital signs, neurological status and laboratory results can be monitored frequently

Clinical and biochemical monitoring

Successful management of DKA and HHS demands **meticulous monitoring** of the patient's clinical and biochemical response to treatment so that timely adjustments in treatment can be made when indicated by the patient's clinical or laboratory data (E).

There should be documentation on a **flow chart** of hour-by-hour clinical observations, IV and oral medications, fluids, and laboratory results. Monitoring should include the following:

- ◆ Hourly (or more frequently as indicated) **vital signs** (heart rate, respiratory rate, blood pressure)
- ◆ Hourly (or more frequently as indicated) **neurological observations** (Glasgow coma score) for warning signs and symptoms of cerebral edema (see below)
 - headache
 - inappropriate slowing of heart rate
 - recurrence of vomiting
 - change in neurological status (restlessness, irritability, increased drowsiness, incontinence) or specific neurologic signs (e.g., cranial nerve palsies, abnormal pupillary responses)
 - rising blood pressure
 - decreased oxygen saturation
- ◆ Amount of administered insulin
- ◆ Hourly (or more frequently as indicated) accurate **fluid input** (including all oral fluid) **and output**
- ◆ **Capillary blood glucose** should be measured hourly (but must be cross-checked against laboratory venous glucose, as capillary methods may be inaccurate in the presence of poor peripheral circulation and acidosis)
- ◆ **Laboratory tests:** serum electrolytes, glucose, blood urea nitrogen, calcium, magnesium, phosphorus,

hematocrit, and blood gases should be repeated 2–4 hourly, or more frequently, as clinically indicated, in more severe cases

- ◆ Urine ketones until cleared or blood β-hydroxybutyrate (BOHB) concentrations, if available, every 2 h (34)
- ◆ If the laboratory cannot provide timely results, a portable biochemical analyzer that measures plasma glucose, serum electrolytes and blood ketones on fingerstick blood samples at the bedside is a useful adjunct to laboratory-based determinations.
- ◆ **Calculations:**
 - Anion gap = Na – (Cl + HCO₃): normal is 12 ± 2 mmol/L
 - In DKA the anion gap is typically 20–30 mmol/L; an anion gap >35 mmol/L suggests concomitant lactic acidosis (E)
 - Corrected sodium = measured Na + 2 × [(plasma glucose – 5.6)/5.6] mmol/L
 - Effective osmolality = 2 × (Na + K) + plasma glucose mOsm/kg

Goals of therapy

- ◆ Correct dehydration
- ◆ Correct acidosis and reverse ketosis
- ◆ Restore blood glucose to near normal
- ◆ Avoid complications of therapy
- ◆ Identify and treat any precipitating event

Fluids and salt. Patients with DKA have a deficit in ECF volume that usually is in the range 5–10% (C) (41, 42). Shock with hemodynamic compromise is rare in pediatric DKA. Clinical estimates of the volume deficit are subjective and inaccurate (43, 44); therefore, in moderate DKA use 5–7% and in severe DKA 7–10% dehydration.

The effective osmolality (formula above) is frequently in the range of 300–350 mmol/kg. Increased serum urea nitrogen and hematocrit may be useful markers of the severity of ECF contraction (40, 45). The serum sodium concentration is an unreliable measure of the degree of ECF contraction for two reasons: (1) glucose, largely restricted to the extracellular space, causes osmotic movement of water into the extracellular space thereby inducing dilutional hyponatremia (46, 47), and (2) the low sodium content of the elevated lipid fraction of the serum in DKA. The latter is not a concern with most modern methods for measuring sodium. Therefore, it is important to calculate the corrected sodium (using the above formula) and monitor its changes throughout the course of therapy. As the plasma glucose concentration decreases after administering fluid and insulin, the measured serum sodium concentration should increase, but it is important to appreciate that this

does not indicate a worsening of the hypertonic state. A failure of measured serum sodium levels to rise or a further decline in serum sodium levels with therapy is thought to be a potentially ominous sign of impending cerebral edema (48–50).

The objectives of fluid and electrolyte replacement therapy are:

- ◆ Restoration of circulating volume
- ◆ Replacement of sodium and the ECF and intracellular fluid deficit of water
- ◆ Improved glomerular filtration with enhanced clearance of glucose and ketones from the blood
- ◆ Reduction of risk of cerebral edema

Principles of water and salt replacement

Despite much effort to find the cause of cerebral edema it remains a mystery. There is no convincing evidence of an association between the rate of fluid or sodium administration used in the treatment of DKA and the development of cerebral edema (51). No treatment strategy can be definitively recommended as being superior to another based on evidence. The principles described below were developed after a comprehensive review of the literature and were accepted and endorsed by a panel of expert physicians representing the Lawson Wilkins Pediatric Endocrine Society (LWPES), the European Society for Paediatric Endocrinology (ESPE), and the International Society for Pediatric and Adolescent Diabetes (ISPAD) (4, 52).

Begin with fluid replacement before insulin therapy. Volume expansion (resuscitation) is required only if needed to restore peripheral circulation. Subsequent fluid administration (including oral fluids) should rehydrate evenly over 48 h at a rate rarely in excess of 1.5–2 times the usual daily maintenance.

- ◆ Water and salt deficits must be replaced (A).
- ◆ IV or oral fluids that may have been given in another facility before assessment should be factored into calculation of deficit and repair (E).
- ◆ *If needed to restore peripheral circulation*, volume expansion (resuscitation) should begin immediately with 0.9% saline (E).
 - The volume and rate of administration depends on circulatory status and, where it is clinically indicated, the volume administered typically is 10–20 mL/kg over 1–2 h, and may be repeated, if necessary (E).
 - Use crystalloid not colloid (E). There are no data to support the use of colloid in preference to crystalloid in the treatment of DKA.
- ◆ *Subsequent* fluid management (deficit replacement) should be with 0.9% saline or Ringer's acetate for at least 4–6 h (C,E) (45, 49, 53–55).

- Thereafter, deficit replacement should be with a solution that has a tonicity equal to or greater than 0.45% saline with added potassium chloride, potassium phosphate, or potassium acetate (see below under potassium replacement) (C,E) (45, 49, 53, 56, 57).
- The rate of fluid (IV and oral) should be calculated to rehydrate evenly over 48 h (C, E) (4, 45).
- As the severity of dehydration may be difficult to determine and frequently is under- or over-estimated (C) (44), infuse fluid each day at a rate rarely in excess of 1.5–2 times the usual daily maintenance requirement based on age, weight, or body surface area (E) (4). See Table 3 for examples of calculations.

- ◆ In addition to clinical assessment of dehydration, calculation of effective osmolality may be valuable to guide fluid and electrolyte therapy (E).
- ◆ Urinary losses should not routinely be added to the calculation of replacement fluid, but may be necessary in rare circumstances (E).
- ◆ The sodium content of the fluid may need to be increased if measured serum sodium is low and does not rise appropriately as the plasma glucose concentration falls (C) (48, 58).
- ◆ The use of large amounts of 0.9% saline has been associated with the development of hyperchloremic metabolic acidosis (59, 60).

Insulin therapy

DKA is caused by a decrease in effective circulating insulin associated with increases in counter-regulatory hormones (glucagon, catecholamines, growth hormone, cortisol). Although rehydration alone causes some decrease in blood glucose concentration (61, 62), insulin therapy is essential to normalize blood glucose and suppress lipolysis and ketogenesis (A) (63).

DKA is caused by either relative or absolute insulin deficiency. Begin with 0.1 U/kg/h. 1–2 h AFTER starting fluid replacement therapy.

Extensive evidence indicates that 'low dose' IV insulin administration should be the standard of care (A) (64).

- ◆ Start insulin infusion 1–2 h after starting fluid replacement therapy, i.e., after the patient has received initial volume expansion (E,C) (65).
- ◆ Correction of insulin deficiency
 - Dose: 0.1 unit/kg/h (for example, one method is to dilute 50 units regular [soluble] insulin in 50 mL normal saline, 1 unit = 1 mL) (64, 66)

Table 3. Shows an alternative example of fluid volumes for the **subsequent phase of rehydration**

Body weight kg	Maintenance mL/24 h	DKA: give maintenance + 5% of body weight/24 h	
		mL/24 h	mL/h
4	325	530	22
5	405	650	27
6	485	790	33
7	570	920	38
8	640	1040	43
9	710	1160	48
10	780	1280	53
11	840	1390	58
12	890	1490	62
13	940	1590	66
14	990	1690	70
15	1030	1780	74
16	1070	1870	78
17	1120	1970	82
18	1150	2050	85
19	1190	2140	89
20	1230	2230	93
22	1300	2400	100
24	1360	2560	107
26	1430	2730	114
28	1490	2890	120
30	1560	3060	128
32	1620	3220	134
34	1680	3360	140
36	1730	3460	144
38	1790	3580	149
40	1850	3700	154
45	1980	3960	165
50	2100	4200	175
55	2210	4420	184
60	2320	4640	193
65	2410	4820	201
70	2500	5000	208
75	2590	5180	216
80	2690	5380	224

After initial resuscitation, and assuming 10% dehydration, the total amount of fluid should be given over 48 h. The Table gives volumes for maintenance and rehydration per 24 h and per hour. If fluid has been given for resuscitation, the volume should **not** be subtracted from the amount shown in the Table. Fluids given orally (when patient has improved) **should** be subtracted from the amount in the table. The Table is based on maintenance volumes according to Darrow (146). For body weights >32 kg, the volumes have been adjusted so as not to exceed twice the maintenance rate of fluid administration.

- Route of administration IV (A)
- An IV bolus is unnecessary (67), may increase the risk of cerebral edema (65), and should *not* be used at the start of therapy (C)
- ◆ The dose of insulin should usually remain at 0.1 unit/kg/h at least until resolution of DKA (pH > 7.30, bicarbonate > 15 mmol/L and/or closure of the anion gap), which invariably takes longer than normalization of blood glucose concentrations (B) (68).

- ◆ If the patient demonstrates marked sensitivity to insulin (e.g., some young children with DKA, patients with HHS, and some older children with established diabetes), the dose may be decreased to 0.05 unit/kg/h, or less, provided that metabolic acidosis continues to resolve.
- ◆ During initial volume expansion the plasma glucose concentration falls steeply (61) (C). Thereafter, and after commencing insulin therapy, the plasma glucose concentration typically decreases at a rate of 2–5 mmol/L/h, depending on the timing and amount of glucose administration (C) (69–75).
- ◆ To prevent an unduly rapid decrease in plasma glucose concentration and hypoglycemia, 5% glucose should be added to the IV fluid (e.g., 5% glucose in 0.45% saline) when the plasma glucose falls to approximately 14–17 mmol/L (250–300 mg/dL), or sooner if the rate of fall is precipitous (B).
 - It may be necessary to use 10% or even 12.5% dextrose to prevent hypoglycemia while continuing to infuse insulin to correct the metabolic acidosis.
- ◆ If blood glucose falls very rapidly (>5 mmol/L/h) after initial fluid expansion consider adding glucose even before plasma glucose has decreased to 17 mmol/L (E).
- ◆ If biochemical parameters of DKA (pH, anion gap) do not improve, reassess the patient, review insulin therapy, and consider other possible causes of impaired response to insulin; e.g., infection, errors in insulin preparation (E).
- ◆ In circumstances where continuous IV administration is not possible, hourly, or 2-hourly subcutaneous (SC) or intramuscular (IM) administration of a short- or rapid-acting insulin analog (insulin lispro or insulin aspart) is safe and may be as effective as IV regular insulin infusion (C) (70, 76–79), but should not be used in subjects whose peripheral circulation is impaired (E).
 - Initial dose SC: 0.3 unit/kg, followed 1 h later by SC insulin lispro or aspart at 0.1 unit/kg every hour, or 0.15–0.20 units/kg every 2 h.
 - If blood glucose falls to <14 mmol/L (250 mg/dL) before DKA has resolved (pH still <7.30), add 5% glucose and continue with insulin as above.
 - When DKA has resolved and blood glucose is <14 mmol/L (250 mg/dL), reduce SC insulin lispro or aspart to 0.05 unit/kg/h to keep blood glucose ≈11 mmol/L (200 mg/dL) until resolution of DKA.

If the blood glucose concentration decreases too quickly or too low before DKA has resolved, increase the amount of glucose administered. Do not decrease the insulin infusion.

Potassium replacement

Children with DKA suffer total body potassium deficits of the order of 3–6 mmol/kg (41, 42, 80–82). The major loss of potassium is from the intracellular pool. Intracellular potassium is depleted because of transcellular shifts of this ion caused by hypertonicity (increased plasma osmolality causes solvent drag in which water and potassium are drawn out of cells) and glycogenolysis and proteolysis secondary to insulin deficiency cause potassium efflux from cells. Potassium is lost from the body from vomiting and as a consequence of osmotic diuresis. Volume depletion causes secondary hyperaldosteronism, which promotes urinary potassium excretion. Thus, total body depletion of potassium occurs, but at presentation serum potassium levels may be normal, increased, or decreased (83). Renal dysfunction, by enhancing hyperglycemia and reducing potassium excretion, contributes to hyperkalemia (83). Administration of insulin and the correction of acidosis will drive potassium back into the cells, decreasing serum levels (84). The serum potassium concentration may decrease abruptly, predisposing the patient to cardiac arrhythmias.

Even with normal or high levels of serum potassium at presentation, there is always a total body deficit of potassium. Begin with 40 mmol potassium/L in the infusate or 20 mmol potassium/L in the hypokalemic patient receiving fluid at a rate >10 mL/kg/h.

- ◆ Replacement therapy is required regardless of the serum potassium concentration (A) (85, 86).
- ◆ If the patient is hypokalemic, start potassium replacement *at the time of* initial volume expansion and before starting insulin therapy. Otherwise, start replacing potassium *after* initial volume expansion and concurrent with starting insulin therapy. If the patient is hyperkalemic, *defer* potassium replacement therapy until urine output is documented (E).
- ◆ If immediate serum potassium measurements are unavailable, an ECG may help to determine whether the child has hyper- or hypokalemia (C) (35, 36). Flattening of the T wave, widening of the QT interval, and the appearance of U waves indicate hypokalemia. Tall, peaked, symmetrical, T waves and shortening of the QT interval are signs of hyperkalemia.
- ◆ The starting potassium concentration in the infusate should be 40 mmol/L. Subsequent potassium replacement therapy should be based on serum potassium measurements (E).
 - If potassium is given with the initial rapid volume expansion, a concentration of 20 mmol/L should be used.
- ◆ Potassium phosphate may be used together with potassium chloride or acetate; e.g., 20 mmol/L

potassium chloride and 20 mmol/L potassium phosphate or 20 mmol/L potassium phosphate and 20 mmol/L potassium acetate (C,E).

- ◆ Potassium replacement should continue throughout IV fluid therapy (E).
- ◆ The maximum recommended rate of IV potassium replacement is usually 0.5 mmol/kg/h (E).
- ◆ If hypokalemia persists despite maximum rate of potassium replacement, then the rate of insulin infusion can be reduced.

Phosphate

Depletion of intracellular phosphate occurs in DKA and phosphate is lost as a result of osmotic diuresis (41, 42, 80). Plasma phosphate levels fall after starting treatment and this is exacerbated by insulin, which promotes entry of phosphate into cells (87–89). Total body phosphate depletion has been associated with a variety of metabolic disturbances (90–92). Clinically significant hypophosphatemia may occur if IV therapy without food intake is prolonged beyond 24 h (41, 42, 80).

- ◆ Prospective studies have not shown clinical benefit from phosphate replacement (A) (93–98).
- ◆ Severe hypophosphatemia in conjunction with unexplained weakness should be treated (E) (99).
- ◆ Administration of phosphate may induce hypocalcemia (C) (100, 101).
- ◆ Potassium phosphate salts may be safely used as an alternative to or combined with potassium chloride or acetate, provided that careful monitoring of serum calcium is performed to avoid hypocalcemia (C) (100, 101).

Acidosis

Severe acidosis is reversible by fluid and insulin replacement; insulin stops further ketoacid production and allows ketoacids to be metabolized, which generates bicarbonate (A). Treatment of hypovolemia improves tissue perfusion and renal function increasing the excretion of organic acids.

Controlled trials have shown no clinical benefit from bicarbonate administration (B,C) (102–105). Bicarbonate therapy may cause paradoxical CNS acidosis (106, 107); rapid correction of acidosis with bicarbonate causes hypokalemia (106, 108, 109), and failure to account for the sodium being administered and appropriately reducing the NaCl concentration of the fluids can result in increasing osmolality (106). Nevertheless, there may be selected patients who may benefit from *cautious* alkali therapy. These include: patients with severe acidemia (arterial pH < 6.9) in whom decreased cardiac contractility and peripheral vasodilatation can further impair tissue perfusion, and patients with life-threatening hyperkalemia (E) (110).

There is no evidence that bicarbonate is either necessary or safe in DKA.

- ◆ Bicarbonate administration is not recommended unless the acidosis is profound and likely to affect adversely the action of adrenaline/epinephrine during resuscitation (A).
- ◆ If bicarbonate is considered necessary, cautiously give 1–2 mmol/kg over 60 min (E).

Complications of therapy

- ◆ Inadequate rehydration
- ◆ Hypoglycemia
- ◆ Hypokalemia
- ◆ Hyperchloremic acidosis
- ◆ Cerebral edema

Introduction of oral fluids and transition to SC insulin injections

- ◆ Oral fluids should be introduced only when substantial clinical improvement has occurred (mild acidosis/ketosis may still be present) (E).
- ◆ When oral fluid is tolerated, IV fluid should be reduced (E).
- ◆ When ketoacidosis has resolved, oral intake is tolerated, and the change to SC insulin is planned, the most convenient time to change to SC insulin is just before a mealtime (E).
- ◆ To prevent rebound hyperglycemia the first SC injection should be given 15–30 min (with rapid-acting insulin) or 1–2 h (with regular insulin) before stopping the insulin infusion to allow sufficient time for the insulin to be absorbed (E). With intermediate- or long-acting insulin, the overlap should be longer and the IV insulin gradually lowered. For example, for patients on a basal-bolus insulin regimen, the first dose of basal insulin may be administered in the evening and the insulin infusion is stopped the next morning (E).
- ◆ The dose and type of SC insulin should be according to local preferences and circumstances.
- ◆ After transitioning to SC insulin, frequent blood glucose monitoring is required to avoid marked hyperglycemia and hypoglycemia (E).

Morbidity and mortality

In national population studies, the mortality rate from DKA in children is 0.15–0.30% (C,B) (111, 112). Cerebral edema accounts for 60–90% of all DKA deaths (C,B) (50, 113). From 10% to 25% of survivors of cerebral edema have significant residual morbidity (C,B) (50, 113, 114).

Other rare causes of morbidity and mortality include:

- ◆ Hypokalemia
- ◆ Hyperkalemia
- ◆ Severe hypophosphatemia
- ◆ Hypoglycemia
- ◆ Other central nervous system complications (disseminated intravascular coagulation, dural sinus thrombosis, basilar artery thrombosis)
- ◆ Peripheral venous thrombosis
- ◆ Sepsis
- ◆ Rhinocerebral or pulmonary mucormycosis
- ◆ Aspiration pneumonia
- ◆ Pulmonary edema
- ◆ Adult respiratory distress syndrome (ARDS)
- ◆ Pneumothorax, pneumomediastinum and SC emphysema
- ◆ Rhabdomyolysis
- ◆ Acute renal failure
- ◆ Acute pancreatitis (115)

Cerebral edema

The incidence of cerebral edema in national population studies is 0.5–0.9% and the mortality rate is 21–24% (50, 113, 114).

Demographic factors that have been associated with an increased risk of cerebral edema include:

- ◆ Younger age (C) (116)
- ◆ New onset diabetes (B) (112) (C) (116)
- ◆ Longer duration of symptoms (C) (117)

These risk associations may reflect the greater likelihood of severe DKA.

In addition, epidemiological studies have identified several potential risk factors at diagnosis or during treatment of DKA. These include:

- ◆ Greater hypocapnia at presentation after adjusting for degree of acidosis (C) (50, 118)
- ◆ Increased serum urea nitrogen at presentation (C) (50)
- ◆ More severe acidosis at presentation (C) (65, 119)
- ◆ Bicarbonate treatment for correction of acidosis (C) (50, 120)
- ◆ An attenuated rise in measured serum sodium concentrations during therapy (C) (48–50)
- ◆ Greater volumes of fluid given in the first 4 h (65)
- ◆ Administration of insulin in the first hour of fluid treatment (65)

Warning signs and symptoms of cerebral edema include:

Headache & slowing of heart rate
Change in neurological status (restlessness, irritability, increased drowsiness, incontinence)
Specific neurological signs (e.g., cranial nerve palsies)
Rising blood pressure
Decreased O₂ saturation

Clinically significant cerebral edema usually develops 4–12 h after treatment has started, but can occur before treatment has begun (50, 114, 121–124) or, uncommonly, may develop as late as 24–48 h after the start of treatment (C,B) (50, 116, 125). Symptoms and signs are variable. A method of clinical diagnosis based on bedside evaluation of neurological state is shown below (C) (126):

Diagnostic criteria.

- ◆ Abnormal motor or verbal response to pain
- ◆ Decorticate or decerebrate posture
- ◆ Cranial nerve palsy (especially III, IV, and VI)
- ◆ Abnormal neurogenic respiratory pattern (e.g., grunting, tachypnea, Cheyne-Stokes respiration, apneusis)

Major criteria.

- ◆ Altered mentation/fluctuating level of consciousness
- ◆ Sustained heart rate deceleration (decrease more than 20 beats per minute) not attributable to improved intravascular volume or sleep state
- ◆ Age-inappropriate incontinence

Minor criteria.

- ◆ Vomiting
- ◆ Headache
- ◆ Lethargy or not easily arousable
- ◆ Diastolic blood pressure > 90 mm Hg
- ◆ Age < 5 yr

One diagnostic criterion, two major criteria, or one major and two minor criteria have a sensitivity of 92% and a false positive rate of only 4%.

A chart with the reference ranges for blood pressure and heart rate, which vary depending on height, weight, and gender, should be readily available, either in the patient's chart or at the bedside.

Have mannitol or hypertonic saline at the bedside and the dose to be given calculated beforehand. In case of profound neurological symptoms, mannitol should be given immediately.

Treatment of cerebral edema

- ◆ Initiate treatment as soon as the condition is suspected.
- ◆ Give mannitol 0.5–1 g/kg IV over 20 min and repeat if there is no initial response in 30 min to 2 h (C,E) (127–129).
- ◆ Reduce the rate of fluid administration by one-third.
- ◆ Hypertonic saline (3%), 5–10 mL/kg over 30 min, may be an alternative to mannitol, especially if there is no initial response to mannitol (C) (130, 131).
 - Mannitol or hypertonic saline should be available at the bedside.

- ◆ Elevate the head of the bed.
- ◆ Intubation may be necessary for the patient with impending respiratory failure, but aggressive hyperventilation (to a pCO₂ < 2.9 kPa [22 mm Hg]) has been associated with poor outcome and is not recommended (C) (132).
- ◆ *After* treatment for cerebral edema has been started, a cranial CT scan should be obtained to rule out other possible intracerebral causes of neurologic deterioration (≈10% of cases), especially thrombosis (133–136) or hemorrhage, which may benefit from specific therapy.

Prevention of recurrent DKA

Management of an episode of DKA is not complete until its cause has been identified and an attempt made to treat it.

All cases of recurrent DKA are preventable

- ◆ Insulin omission, either inadvertently or deliberately, is the cause in most cases (C, A) (28, 30).
- ◆ The most common cause of DKA in insulin pump users is failure to take extra insulin with a pen or syringe when hyperglycemia and hyperketonemia or ketonuria occur (E).
- ◆ Home measurement of blood BOHB concentrations, when compared with urine ketone testing, decreases diabetes-related hospital visits (both emergency department visits and hospitalizations) by the early identification and treatment of ketosis (137). Blood BOHB measurements may be especially valuable to prevent DKA in patients who use a pump because interrupted insulin delivery rapidly leads to ketosis (E).
 - There may be dissociation between urine ketone and serum BOHB concentrations, which may be increased to levels consistent with DKA when a urine ketone test is negative or shows only trace or small ketonuria (138).
- ◆ There usually is an important psychosocial reason for insulin omission.
 - an attempt to lose weight in an adolescent girl with an eating disorder,
 - a means of escaping an intolerable or abusive home situation,
 - clinical depression or other reason for inability of the patient to manage the diabetes unassisted.
- ◆ An infection that is not associated with vomiting and diarrhea is seldom the cause when the patient/family is properly educated in diabetes management and is receiving appropriate follow-up care by

- a diabetes team with a 24-h telephone helpline (B) (139–141).
- ◆ A psychiatric social worker or clinical psychologist should be consulted to identify the psychosocial reason(s) contributing to development of DKA (E).
 - ◆ Insulin omission can be prevented by schemes that provide education, psychosocial evaluation and treatment combined with adult supervision of insulin administration (B) (142).
 - Parents and patients should learn how to recognize and treat impending DKA with additional rapid- or short-acting insulin and oral fluids (E)
 - Patients should have access to a 24-h telephone helpline for emergency advice and treatment (B) (139)
 - When a responsible adult administers insulin there may be as much as a tenfold reduction in frequency of recurrent DKA (B) (142).

This article is a Chapter in the ISPAD Clinical Practice Consensus Guidelines 2006–2007 of the International Society for Pediatric and Adolescent Diabetes (ISPAD, www.ispad.org). The complete set of these Guidelines will later be published as a compendium. Additional comments, clarifications or corrections should be directed to the Corresponding Author.

The evidence grading system used in the ISPAD Guidelines is the same as that used by the American Diabetes Association. See the Introduction of the ISPAD Clinical Practice Consensus Guidelines in *Pediatric Diabetes* 2006; 7: 341–342.

References

1. FOSTER DW, MCGARRY JD. The metabolic derangements and treatment of diabetic ketoacidosis. *N Engl J Med* 1983; 309: 159–169.
2. KITABCHI A, UMPIERREZ G, MURPHY M et al. Management of hyperglycemic crises in patients with diabetes. *Diabetes Care* 2001; 24: 131–153.
3. McDONNELL CM, PEDREIRA CC, VADAMALAYAN B, CAMERON FJ, WERTHER GA. Diabetic ketoacidosis, hyperosmolarity and hypernatremia: are high-carbohydrate drinks worsening initial presentation? *Pediatr Diabetes* 2005; 6: 90–94.
4. DUNGER DB, SPERLING MA, ACERINI CL et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. *Arch Dis Child* 2004; 89: 188–194.
5. BURGE MR, HARDY KJ, SCHADE DS. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. *J Clin Endocrinol Metab* 1993; 76: 1192–1198.
6. PINKEY JH, BINGLEY PJ, SAWTELL PA, DUNGER DB, GALE EA. Presentation and progress of childhood diabetes mellitus: a prospective population-based study. The Bart's-Oxford Study Group. *Diabetologia* 1994; 37: 70–74.
7. AMERICAN DIABETES ASSOCIATION. Type 2 diabetes in children and adolescents. (Consensus statement). *Diabetes Care* 2000; 23: 381–389.
8. PINHAS-HAMIEL O, DOLAN LM, ZEITLER PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. *Diabetes Care* 1997; 20: 484–486.
9. SCOTT CR, SMITH JM, CRADOCK MM, PIHOKER C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. *Pediatrics* 1997; 100: 84–91.
10. NEUFELD ND, RAFFEL LJ, LONDON C, CHEN YD, VADHEIM CM. Early presentation of type 2 diabetes in Mexican-American youth. *Diabetes Care* 1998; 21: 80–86.
11. SELLERS EA, DEAN HJ. Diabetic ketoacidosis: a complication of type 2 diabetes in Canadian aboriginal youth. *Diabetes Care* 2000; 23: 1202–1204.
12. LIPTON R, KEENAN H, ONYEMERE KU, FREELS S. Incidence and onset features of diabetes in African-American and Latino children in Chicago, 1985–1994. *Diabetes Metab Res Rev* 2002; 18: 135–142.
13. ZDRAVKOVIC V, DANEMAN D, HAMILTON J. Presentation and course of Type 2 diabetes in youth in a large multi-ethnic city. *Diabet Med* 2004; 21: 1144–1148.
14. YOKOTA Y, KIKUCHI N, MATSUURA N. Screening for diabetes by urine glucose testing at school in Japan. *Pediatr Diabetes* 2004; 5: 212–218.
15. URAKAMI T, KUBOTA S, NITADORI Y, HARADA K, OWADA M, KITAGAWA T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. *Diabetes Care* 2005; 28: 1876–1881.
16. SUGIHARA S, SASAKI N, KOHNO H et al. Survey of current medical treatments for childhood-onset type 2 diabetes mellitus. *Jpn Clin Pediatr Endocrinol* 2005; 14: 65–75.
17. CHASE HP, GARG SK, JELLEY DH. Diabetic ketoacidosis in children and the role of outpatient management. *Pediatr Rev* 1990; 11: 297–304.
18. MORALES AE, ROSENBLUM AL. Death caused by hyperglycemic hyperosmolar state at the onset of type 2 diabetes. *J Pediatr* 2004; 144: 270–273.
19. KERSHAW MJ, NEWTON T, BARRETT TG, BERRY K, KIRK J. Childhood diabetes presenting with hyperosmolar dehydration but without ketoacidosis: a report of three cases. *Diabet Med* 2005; 22: 645–647.
20. LEVY-MARCHAL C, PAPOZ L, DE BEAUFORT C et al. Clinical and laboratory features of type 1 diabetic children at the time of diagnosis. *Diabet Med* 1992; 9: 279–284.
21. KOMULAINEN J, LOUNAMAA R, KNIP M, KAPRIO EA, AKERBLUM HK. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Childhood Diabetes in Finland Study Group. *Arch Dis Child* 1996; 75: 410–415.
22. LEVY-MARCHAL C, PATTERSON CC, GREEN A. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. *European and Diabetes. Diabetologia* 2001; 44(Suppl. 3): B75–B80.
23. HANAS R, LINDBLAD B, LINDGREN F. Diabetic ketoacidosis and cerebral edema in Sweden – a 2-year population study. *Diabetes* 2004; 53(Suppl. 2): A421.
24. REWERS A, KLINGENSMITH G, DAVIS C et al. Diabetic ketoacidosis at onset of diabetes: the SEARCH for diabetes in youth study. *Diabetes* 2005; 54(Suppl. 1): A63.
25. KOMULAINEN J, KULMALA P, SAVOLA K et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. *Diabetes Care* 1999; 22: 1950–1955.

26. ROSILIO M, COTTON JB, WIELICZKO MC et al. Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. *Diabetes Care* 1998; 21: 1146–1153 (See comments)
27. SMITH CP, FIRTH D, BENNETT S, HOWARD C, CHISHOLM P. Ketoacidosis occurring in newly diagnosed and established diabetic children. *Acta Paediatr* 1998; 87: 537–541.
28. REWERS A, CHASE HP, MACKENZIE T et al. Predictors of acute complications in children with type 1 diabetes. *JAMA* 15 2002; 287: 2511–2518.
29. HANAS R, LINDBLAD B, LINDGREN F. Predisposing conditions and insulin pump use in a 2-year population study of pediatric ketoacidosis in Sweden. *Diabetes* 2005; 54(Suppl. 1): A455.
30. MORRIS AD, BOYLE DI, MCMAHON AD, GREENE SA, MACDONALD TM, NEWTON RW. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. *Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet* 1997; 350: 1505–1510.
31. STEINER MJ, DEWALT DA, BYERLEY JS. Is this child dehydrated? *JAMA* 2004; 291: 2746–2754.
32. TEASDALE G, JENNETT B. Assessment of coma and impaired consciousness. A practical scale. *Lancet* 1974; 2: 81–84.
33. WIGGAM MI, O'KANE MJ, HARPER R et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. *Diabetes Care* 1997; 20: 1347–1352.
34. HAM MR, OKADA P, WHITE PC. Bedside ketone determination in diabetic children with hyperglycemia and ketosis in the acute care setting. *Pediatr Diabetes* 2004; 5: 39–43.
35. MALONE JI, BRODSKY SJ. The value of electrocardiogram monitoring in diabetic ketoacidosis. *Diabetes Care* 1980; 3: 543–547.
36. SOLER NG, BENNETT MA, FITZGERALD MG, MALINS JM. Electrocardiogram as a guide to potassium replacement in diabetic ketoacidosis. *Diabetes* 1974; 23: 610–615.
37. MALONE JI, ROOT AW. Plasma free insulin concentrations: keystone to effective management of diabetes mellitus in children. *J Pediatr* 1981; 99: 862–867.
38. MONROE KW, KING W, ATCHISON JA. Use of PRISM scores in triage of pediatric patients with diabetic ketoacidosis. *Am J Manag Care* 1997; 3: 253–258.
39. BONADIO WA, GUTZEIT MF, LOSEK JD, SMITH DS. Outpatient management of diabetic ketoacidosis. *Am J Dis Child* 1988; 142: 448–450.
40. LINARES MY, SCHUNK JE, LINDSAY R. Laboratory presentation in diabetic ketoacidosis and duration of therapy. *Pediatr Emerg Care* 1996; 12: 347–351.
41. ATCHLEY D, LOEB R, RICHARDS D Jr, BENEDICT E, DRISCOLL M. On diabetic ketoacidosis: a detailed study of electrolyte balances following the withdrawal and reestablishment of insulin therapy. *J Clin Invest* 1933; 12: 297–326.
42. NABARRO J, SPENCER A, STOWERS J. Metabolic studies in severe diabetic ketosis. *Q J Med* 1952; 82: 225–248.
43. MACKENZIE A, BARNES G, SHANN F. Clinical signs of dehydration in children. *Lancet* 1989; 2: 605–607.
44. KOVES IH, NEUTZE J, DONATH S et al. The accuracy of clinical assessment of dehydration during diabetic ketoacidosis in childhood. *Diabetes Care* 2004; 27: 2485–2487.
45. HARRIS GD, FIORDALISI I. Physiologic management of diabetic ketoacidemia. A 5-year prospective pediatric experience in 231 episodes. *Arch Pediatr Adolesc Med* 1994; 148: 1046–1052.
46. KATZ MA. Hyperglycemia-induced hyponatremia – calculation of expected serum sodium depression. *N Engl J Med* 1973; 289: 843–844.
47. HILLIER TA, ABBOTT RD, BARRETT EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. *Am J Med* 1999; 106: 399–403.
48. HARRIS GD, FIORDALISI I, HARRIS WL, MOSOVICH LL, FINBERG L. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study. *J Pediatr* 1990; 117: 22–31.
49. HALE PM, REZVANI I, BRAUNSTEIN AW, LIPMAN TH, MARTINEZ N, GARIBALDI L. Factors predicting cerebral edema in young children with diabetic ketoacidosis and new onset type I diabetes. *Acta Paediatr* 1997; 86: 626–631.
50. GLASER N, BARNETT P, MCCASLIN I et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. *N Engl J Med* 2001; 344: 264–269.
51. BROWN TB. Cerebral oedema in childhood diabetic ketoacidosis: is treatment a factor? *Emerg Med J* 2004; 21: 141–144.
52. DUNGER DB, SPERLING MA, ACERINI CL et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. *Pediatrics* 2004; 113: e133–e140.
53. ADROGUE HJ, BARRERO J, EKNONYAN G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. *JAMA* 1989; 262: 2108–2113.
54. MEL JM, WERTHER GA. Incidence and outcome of diabetic cerebral oedema in childhood: are there predictors? *J Paediatr Child Health* 1995; 31: 17–20.
55. WAGNER A, RISSE A, BRILL HL et al. Therapy of severe diabetic ketoacidosis. Zero-mortality under very-low-dose insulin application. *Diabetes Care* 1999; 22: 674–677.
56. ROTHER KI, SCHWENK WFN. Effect of rehydration fluid with 75 mmol/L of sodium on serum sodium concentration and serum osmolality in young patients with diabetic ketoacidosis. *Mayo Clin Proc* 1994; 69: 1149–1153.
57. FELNER EI, WHITE PC. Improving management of diabetic ketoacidosis in children. *Pediatrics* 2001; 108: 735–740.
58. DUCK SC, WYATT DT. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. *J Pediatr* 1988; 113: 10–14.
59. ADROGUE HJ, EKNONYAN G, SUKI WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. *Kidney Int* 1984; 25: 591–598.
60. OH MS, CARROLL HJ, URIBARRI J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. *Nephron* 1990; 54: 1–6.
61. WALDHAUSL W, KLEINBERGER G, KORN A, DUDCZAK R, BRATUSCH-MARRAIN P, NOWOTNY P. Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration. *Diabetes* 1979; 28: 577–584.
62. OWEN OE, LICHT JH, SAPIR DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. *Diabetes* 1981; 30: 510–518.

63. LUZI L, BARRETT EJ, GROOP LC, FERRANNINI E, DEFRONZO RA. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. *Diabetes* 1988; 37: 1470–1477.
64. KITABCHI AE. Low-dose insulin therapy in diabetic ketoacidosis: fact or fiction? *Diabetes Metab Rev* 1989; 5: 337–363.
65. EDGE J, JAKES R, ROY Y et al. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. *Diabetologia* 2006; 49: 2002–2009.
66. SCHADE DS, EATON RP. Dose response to insulin in man: differential effects on glucose and ketone body regulation. *J Clin Endocrinol Metab* 1977; 44: 1038–1053.
67. LINDSAY R, BOLTE RG. The use of an insulin bolus in low-dose insulin infusion for pediatric diabetic ketoacidosis. *Pediatr Emerg Care* 1989; 5: 77–79.
68. SOLER NG, FITZGERALD MG, WRIGHT AD, MALINS JM. Comparative study of different insulin regimens in management of diabetic ketoacidosis. *Lancet* 1975; 2: 1221–1224.
69. MARTIN MM, MARTIN AA. Continuous low-dose infusion of insulin in the treatment of diabetic ketoacidosis in children. *J Pediatr* 1976; 89: 560–564.
70. FISHER JN, SHAHSHAHANI MN, KITABCHI AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. *N Engl J Med* 1977; 297: 238–241.
71. LIGHTNER ES, KAPPY MS, REVSIN B. Low-dose intravenous insulin infusion in patients with diabetic ketoacidosis: biochemical effects in children. *Pediatrics* 1977; 60: 681–688.
72. KAPPY MS, LIGHTNER ES. Low-dose intravenous insulin in the treatment of diabetic ketoacidosis. *Am J Dis Child* 1979; 133: 523–525.
73. DROP SL, DUVAL-ARNOULD JM, GOBER AE, HERSH JH, MCENERY PT, KNOWLES HC. Low-dose intravenous insulin infusion versus subcutaneous insulin injection: a controlled comparative study of diabetic ketoacidosis. *Pediatrics* 1977; 59: 733–738.
74. EDWARDS GA, KOHAUT EC, WEHRING B, HILL LL. Effectiveness of low-dose continuous intravenous insulin infusion in diabetic ketoacidosis. A prospective comparative study. *J Pediatr* 1977; 91: 701–705.
75. BURGHEEN GA, ETTELDORF JN, FISHER JN, KITABCHI AQ. Comparison of high-dose and low-dose insulin by continuous intravenous infusion in the treatment of diabetic ketoacidosis in children. *Diabetes Care* 1980; 3: 15–20.
76. SACKS HS, SHAHSHAHANI M, KITABCHI AE, FISHER JN, YOUNG RT. Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion. *Ann Intern Med* 1979; 90: 36–42.
77. UMPIERREZ GE, LATIF K, STOEVER J et al. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. *Am J Med* 2004; 117: 291–296.
78. UMPIERREZ GE, CUERVO R, KARABELL A, LATIF K, FREIRE AX, KITABCHI AE. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. *Diabetes Care* 2004; 27: 1873–1878.
79. DELLA MANNA T, STEINMETZ L, CAMPOS PR et al. Subcutaneous Use of a Fast-Acting Insulin Analog: An alternative treatment for pediatric patients with diabetic ketoacidosis. *Diabetes Care* 2005; 28: 1856–1861.
80. BUTLER A, TALBOT N, BURNETT C, STANBURY J, MACLACHLAN E. Metabolic studies in diabetic coma. *Trans Assoc Am Phys* 1947; 60: 102–109.
81. DANOWSKI T, PETERS J, RATHBUN J, QUASHNOCK J, GREENMAN L. Studies in diabetic acidosis and coma, with particular emphasis on the retention of administered potassium. *J Clin Invest* 1949; 28: 1–9.
82. DARROW D, PRATT E. Retention of water and electrolyte during recovery in a patient with diabetic acidosis. *J Pediatr* 1952; 41: 688–696.
83. ADROGUE HJ, LEDERER ED, SUKI WN, EKNOYAN G. Determinants of plasma potassium levels in diabetic ketoacidosis. *Medicine (Baltimore)* 1986; 65: 163–172.
84. DEFRONZO RA, FELIG P, FERRANNINI E, WAHREN J. Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. *Am J Physiol* 1980; 238:E421–427.
85. TATTERSALL RB. A paper which changed clinical practice (slowly). Jacob Holler on potassium deficiency in diabetic acidosis (1946). *Diabet Med* 1999; 16: 978–984.
86. NABARRO JD, SPENCER AG, STOWERS JM. Treatment of diabetic ketosis. *Lancet* 17 1952; 1: 983–989.
87. GUEST G. Organic phosphates of the blood and mineral metabolism in diabetic acidosis. *Am J Dis Child* 1942; 64: 401–412.
88. GUEST G, RAPOPORT S. Electrolytes of blood plasma and cells in diabetic acidosis and during recovery. *Proc Am Diabetes Assoc* 1947; 7: 95–115.
89. RILEY MS, SCHADE DS, EATON RP. Effects of insulin infusion on plasma phosphate in diabetic patients. *Metabolism* 1979; 28: 191–194.
90. ALBERTI KG, EMERSON PM, DARLEY JH, HOCKADAY TD. 2,3-Diphosphoglycerate and tissue oxygenation in uncontrolled diabetes mellitus. *Lancet* 26 1972; 2: 391–395.
91. KNOCHEL JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. *Arch Intern Med* 1977; 137: 203–220.
92. O'CONNOR LR, WHEELER WS, BETHUNE JE. Effect of hypophosphatemia on myocardial performance in man. *N Engl J Med* 1977; 297: 901–903.
93. GIBBY OM, VEALE KE, HAYES TM, JONES JG, WARDROP CA. Oxygen availability from the blood and the effect of phosphate replacement on erythrocyte 2,3-diphosphoglycerate and haemoglobin-oxygen affinity in diabetic ketoacidosis. *Diabetologia* 1978; 15: 381–385.
94. KELLER U, BERGER W. Prevention of hypophosphatemia by phosphate infusion during treatment of diabetic ketoacidosis and hyperosmolar coma. *Diabetes* 1980; 29: 87–95.
95. WILSON HK, KEUER SP, LEA AS, BOYD AE 3rd, EKNOYAN G. Phosphate therapy in diabetic ketoacidosis. *Arch Intern Med* 1982; 142: 517–520.
96. BECKER DJ, BROWN DR, STERANKA BH, DRASH AL. Phosphate replacement during treatment of diabetic ketosis. Effects on calcium and phosphorus homeostasis. *Am J Dis Child* 1983; 137: 241–246.
97. FISHER JN, KITABCHI AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. *J Clin Endocrinol Metab* 1983; 57: 177–180.
98. CLERBAUX T, REYNAERT M, WILLEMS E, FRANS A. Effect of phosphate on oxygen-hemoglobin affinity, diphosphoglycerate and blood gases during recovery from diabetic ketoacidosis. *Intensive Care Med* 1989; 15: 495–498.
99. BOHANNON NJ. Large phosphate shifts with treatment for hyperglycemia. *Arch Intern Med* 1989; 149: 1423–1425.
100. ZIPF WB, BACON GE, SPENCER ML, KELCH RP, HOPWOOD NJ, HAWKER CD. Hypocalcemia, hypomagnesemia, and transient hypoparathyroidism during

- therapy with potassium phosphate in diabetic ketoacidosis. *Diabetes Care* 1979; 2: 265–268.
101. WINTER RJ, HARRIS CJ, PHILLIPS LS, GREEN OC. Diabetic ketoacidosis. Induction of hypocalcemia and hypomagnesemia by phosphate therapy. *Am J Med* 1979; 67: 897–900.
 102. HALE PJ, CRASE J, NATTRASS M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. *BMJ (Clin Res Ed)* 1984; 289: 1035–1038.
 103. MORRIS LR, MURPHY MB, KITABCHI AE. Bicarbonate therapy in severe diabetic ketoacidosis. *Ann Intern Med* 1986; 105: 836–840.
 104. OKUDA Y, ADROGUE HJ, FIELD JB, NOHARA H, YAMASHITA K. Counterproductive effects of sodium bicarbonate in diabetic ketoacidosis. *J Clin Endocrinol Metab* 1996; 81: 314–320.
 105. GREEN SM, ROTHROCK SG, HO JD et al. Failure of adjunctive bicarbonate to improve outcome in severe pediatric diabetic ketoacidosis. *Ann Emerg Med* 1998; 31: 41–48.
 106. ASSAL JP, AOKI TT, MANZANO FM, KOZAK GP. Metabolic effects of sodium bicarbonate in management of diabetic ketoacidosis. *Diabetes* 1974; 23: 405–411.
 107. OHMAN JL Jr, MARLISS EB, AOKI TT, MUNICHOODAPPA CS, KHANNA VV, KOZAK GP. The cerebrospinal fluid in diabetic ketoacidosis. *N Engl J Med* 1971; 284: 283–290.
 108. SOLER NG, BENNETT MA, DIXON K, FITZGERALD MG, MALINS JM. Potassium balance during treatment of diabetic ketoacidosis with special reference to the use of bicarbonate. *Lancet* 1972; 2: 665–667.
 109. LEVER E, JASPAN JB. Sodium bicarbonate therapy in severe diabetic ketoacidosis. *Am J Med* 1983; 75: 263–268.
 110. NARINS RG, COHEN JJ. Bicarbonate therapy for organic acidosis: the case for its continued use. *Ann Intern Med* 1987; 106: 615–618.
 111. CURTIS JR, TO T, MUIRHEAD S, CUMMINGS E, DANEMAN D. Recent trends in hospitalization for diabetic ketoacidosis in Ontario children. *Diabetes Care* 2002; 25: 1591–1596.
 112. EDGE JA, FORD-ADAMS ME, DUNGER DB. Causes of death in children with insulin dependent diabetes 1990–96. *Arch Dis Child* 1999; 81: 318–323.
 113. EDGE JA, HAWKINS MM, WINTER DL, DUNGER DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. *Arch Dis Child* 2001; 85: 16–22.
 114. LAWRENCE SE, CUMMINGS EA, GABOURY I, DANEMAN D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. *J Pediatr* 2005; 146: 688–692.
 115. HADDAD NG, CROFFIE JM, EUGSTER EA. Pancreatic enzyme elevations in children with diabetic ketoacidosis. *J Pediatr* 2004; 145: 122–124.
 116. ROSENBLUM AL. Intracerebral crises during treatment of diabetic ketoacidosis. *Diabetes Care* 1990; 13: 22–33.
 117. BELLO FA, SOTOS JF. Cerebral oedema in diabetic ketoacidosis in children. *Lancet* 1990; 336: 64 (Letter)
 118. MAHONEY CP, VLCEK BW, DELAGUILA M. Risk factors for developing brain herniation during diabetic ketoacidosis. *Pediatr Neurol* 1999; 21: 721–727.
 119. DURR JA, HOFFMAN WH, SKLAR AH, EL GAMMAL T, STEINHART CM. Correlates of brain edema in uncontrolled IDDM. *Diabetes* 1992; 41: 627–632.
 120. BUREAU MA, BEGIN R, BERTHIAUME Y, SHAPCOTT D, KHOURY K, GAGNON N. Cerebral hypoxia from bicarbonate infusion in diabetic acidosis. *J Pediatr* 1980; 96: 968–973.
 121. DEEB L. Development of fatal cerebral edema during outpatient therapy for diabetic ketoacidosis. *Pract Diab* 1989; 6: 212–213.
 122. GLASGOW AM. Devastating cerebral edema in diabetic ketoacidosis before therapy. *Diabetes Care* 1991; 14: 77–78 (Letter)
 123. COUCH RM, ACOTT PD, WONG GW. Early onset fatal cerebral edema in diabetic ketoacidosis. *Diabetes Care* 1991; 14: 78–79.
 124. FIORDALISI I, HARRIS GD, GILLILAND MG. Prehospital cardiac arrest in diabetic ketoacidemia: why brain swelling may lead to death before treatment. *J Diabetes Complications* 2002; 16: 214–219.
 125. EDGE JA. Cerebral oedema during treatment of diabetic ketoacidosis: are we any nearer finding a cause? *Diabetes Metab Res Rev* 2000; 16: 316–324.
 126. MUIR AB, QUISLING RG, YANG MC, ROSENBLUM AL. Cerebral Edema in Childhood Diabetic Ketoacidosis: Natural history, radiographic findings, and early identification. *Diabetes Care* 2004; 27: 1541–1546.
 127. FRANKLIN B, LIU J, GINSBERG-FELLNER F. Cerebral edema and ophthalmoplegia reversed by mannitol in a new case of insulin-dependent diabetes mellitus. *Pediatrics* 1982; 69: 87–90.
 128. SHABIR N, OBERFIELD SE, CORRALES R, KAIRAM R, LEVINE LS. Recovery from symptomatic brain swelling in diabetic ketoacidosis. *Clin Pediatr (Phila)* 1992; 31: 570–573.
 129. ROBERTS MD, SLOVER RH, CHASE HP. Diabetic ketoacidosis with intracerebral complications. *Pediatr Diabetes* 2001; 2: 109–114.
 130. CURTIS JR, BOHN D, DANEMAN D. Use of hypertonic saline in the treatment of cerebral edema in diabetic ketoacidosis (DKA). *Pediatr Diabetes* 2001; 2: 191–194.
 131. KAMAT P, VATS A, GROSS M, CHECCHIA PA. Use of hypertonic saline for the treatment of altered mental status associated with diabetic ketoacidosis. *Pediatr Crit Care Med* 2003; 4: 239–242.
 132. MARCIN JP, GLASER N, BARNETT P et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. *J Pediatr* 2002; 141: 793–797.
 133. KANTER RK, OLIPHANT M, ZIMMERMAN JJ, STUART MJ. Arterial thrombosis causing cerebral edema in association with diabetic ketoacidosis. *Crit Care Med* 1987; 15: 175–176.
 134. ROE TF, CRAWFORD TO, HUFF KR, COSTIN G, KAUFMAN FR, NELSON MD, Jr. Brain infarction in children with diabetic ketoacidosis. *J Diabetes Complications* 1996; 10: 100–108.
 135. KEANE S, GALLAGHER A, ACKROYD S, MCSHANE MA, EDGE JA. Cerebral venous thrombosis during diabetic ketoacidosis. *Arch Dis Child* 2002; 86: 204–205.
 136. ROSENBLUM AL. Fatal cerebral infarctions in diabetic ketoacidosis in a child with previously unknown heterozygosity for factor V Leiden deficiency. *J Pediatr* 2004; 145: 561–562.
 137. LAFFEL LM, WENTZELL K, LOUGHLIN C, TOVAR A, MOLTZ K, BRINK S. Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial. *Diabet Med* 2006; 23: 278–284.
 140. LAFFEL L. Sick-day management in type 1 diabetes. *Endocrinol Metab Clin North Am* 2000; 29: 707–723.
 139. HOFFMAN WH, O'NEILL P, KHOURY C, BERNSTEIN SS. Service and education for the insulin-dependent child. *Diabetes Care* 1978; 1: 285–288.

140. DROZDA DJ, DAWSON VA, LONG DJ, FRESON LS, SPERLING MA. Assessment of the effect of a comprehensive diabetes management program on hospital admission rates of children with diabetes mellitus. *Diabetes Educ* 1990; 16: 389–393.
141. GREY M, BOLAND EA, DAVIDSON M, LI J, TAMBORLANE WV. Coping skills training for youth with diabetes mellitus has long-lasting effects on metabolic control and quality of life. *J Pediatr* 2000; 137: 107–113.
142. GOLDEN MP, HERROLD AJ, ORR DP. An approach to prevention of recurrent diabetic ketoacidosis in the pediatric population. *J Pediatr* 1985; 107: 195–200.
143. HOLLIDAY MA, SEGAR WE. The maintenance need for water in parenteral fluid therapy. *Pediatrics* 1957; 19: 823–832.
144. FRIEDMAN AL. Pediatric hydration therapy: historical review and a new approach. *Kidney Int* 2005; 67: 380–388.
145. HENDRICKS K, DUGGAN C., eds. *Manual of Pediatric Nutrition*, 4th edn. Hamilton, Ontario: BC Decker, 2005
146. DARROW DC. The physiologic basis for estimating requirements for parenteral fluids. *Pediatr Clin North Am* 1959; 6: 29–41.